Literature DB >> 12057125

Autoimmunity in chronic lymphocytic leukemia.

J H Ward1.   

Abstract

Chronic lymphocytic leukemia (CLL) is associated with the immune-mediated disorders autoimmune hemolytic anemia and immune thrombocytopenia. Initial treatment with corticosteroids is often successful in controlling these manifestations, but splenectomy should be considered if a rapid and complete response is not obtained. For those with persistent anemia or thrombocytopenia after splenectomy, treatment directed against the underlying CLL may be considered, although the use of purine analogues has also precipitated autoimmune hemolytic anemia. Pure red cell aplasia has been reported in CLL, and usually responds to immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12057125     DOI: 10.1007/s11864-001-0039-z

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  26 in total

Review 1.  Complications in the treatment of CLL with purine analogues.

Authors:  G Juliusson
Journal:  Hematol Cell Ther       Date:  1997-11

Review 2.  Impairments in immune cell function in B cell chronic lymphocytic leukemia.

Authors:  M M Bartik; D Welker; N E Kay
Journal:  Semin Oncol       Date:  1998-02       Impact factor: 4.929

Review 3.  Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases.

Authors:  T J Kipps; D A Carson
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

Review 4.  Chronic idiopathic thrombocytopenic purpura.

Authors:  J N George; M A el-Harake; G E Raskob
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

5.  Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.

Authors:  G Juliusson; A Elmhorn-Rosenborg; J Liliemark
Journal:  N Engl J Med       Date:  1992-10-08       Impact factor: 91.245

6.  Combination chemotherapy in refractory immune thrombocytopenic purpura.

Authors:  M Figueroa; J Gehlsen; D Hammond; S Ondreyco; L Piro; T Pomeroy; F Williams; R McMillan
Journal:  N Engl J Med       Date:  1993-04-29       Impact factor: 91.245

7.  Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia.

Authors:  J C Weeks; M R Tierney; M C Weinstein
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

8.  Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CDA).

Authors:  R C Chasty; H Myint; D G Oscier; J A Orchard; D P Bussutil; M D Hamon; A G Prentice; J A Copplestone
Journal:  Leuk Lymphoma       Date:  1998-04

Review 9.  Advances in the biology and treatment of B-cell chronic lymphocytic leukemia.

Authors:  S O'Brien; A del Giglio; M Keating
Journal:  Blood       Date:  1995-01-15       Impact factor: 22.113

10.  2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.

Authors:  A Saven; R H Lemon; M Kosty; E Beutler; L D Piro
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

View more
  3 in total

Review 1.  New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.

Authors:  Folke Schriever; Dieter Huhn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Rituximab responsive multiple radiculopathies and cranial nerve palsies in association with chronic lymphocytic leukaemia.

Authors:  Jasper M Morrow; Shirley D'Sa; Rupert A Page; Mahir Al Hilali; Michael P Lunn; Mary M Reilly
Journal:  J Neurol       Date:  2011-09-02       Impact factor: 4.849

3.  Reduced cell turnover in bovine leukemia virus-infected, persistently lymphocytotic cattle.

Authors:  Christophe Debacq; Becca Asquith; Michal Reichert; Arsène Burny; Richard Kettmann; Luc Willems
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.